Amag Pharmaceuticals Inc. said the company would divest two of women’s health products, after the drugmaker conducted a strategic review under pressure from hedge fund Caligan Partners.
Apple Inc. launched an app that will let users of the company’s devices to enroll in three health studies, allowing them to share health-related data for medical research.
The U.S. Food and Drug Administration approved South African drugmaker Aspen Pharmacare’s hydroxyprogesterone caproate (HPC), which is used to prevent preterm birth in pregnant women.
Sumitomo Dainippon Pharma and Roivant Sciences Create Broad Strategic Alliance for New Medicines
Alliances, Biopharmaceutical, Business, Drug Distribution, Market Access, Market exclusivity, New Medicines, Pediatric Rare Diseases, Prostate Cancer, Respiratory Disease, Stakes, Urinary Diseases, Women’s HealthThe Sumitomo Dainippon-Roivant Alliance encompasses up to 11 biopharmaceutical Vants with more than 25 innovative clinical programs and multiple potential product launches from 2020 to 2022, and access to key elements of Roivant’s proprietary technology platforms including DrugOme and Digital Innovation.
Older women who take supplements with high doses of vitamins B6 and B12 may be more likely than their counterparts who do not to experience hip fractures, a U.S. study suggests.
Outcome Health, which provides health education at the moment of care to improve patient outcomes, announced today an initiative with WomenHeart: The National Coalition for Women with Heart Disease, the first national patient-centered organization solely focused on women’s heart disease.
Myovant Sciences made four key appointments to its managing team. Matthew Lang, J.D., joined the company as general counsel and corporate secretary; Juan Camilo Arjona Ferreira, M.D., came aboard as chief medical officer; Teresa Perney, Ph.D., was appointed senior VP of Regulatory Affairs and Quality Assurance; and Andria Langenberg, M.D., was tapped as head of Drug Safety and Pharmacovigilance.
Virtus Pharmaceuticals Inc. – a specialty niche pharmaceutical company and part of the Linden Capital Partners portfolio – announced it launched Prometrium (Progesterone, USP Capsules), the company’s first branded product.
